Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 1532-1537, May 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rahman, A.
Right arrow Articles by Schein, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rahman, A.
Right arrow Articles by Schein, P. S.

Liposomal Protection of Adriamycin-induced Cardiotoxicity in Mice1

Aquilur Rahman2, Andrea Kessler, Newton More, Branimir Sikic, Geoffrey Rowden, Paul Woolley and Philip S. Schein

Division of Medical Oncology [A. R., A. K., B. S., P. W., P. S.] and Department of Pathology [N. M., G. R.], School of Medicine, Vincent T. Lombardi Cancer Research Center, Georgetown University Hospital, Washington, D. C. 20007

The pharmacological and therapeutic effects of Adriamycin entrapped in positively charged and negatively charged liposomes were compared with those of free Adriamycin in mice. Liposomes were composed of phosphatidylcholine and cholesterol mixed with stearyl amine (positive charge) or phosphatidylserine (negative charge). Positive liposomes with entrapped Adriamycin effectively retarded the in vivo uptake of drug in cardiac tissue when compared to free drug or drug entrapped in negative liposomes. At 4 mg/kg i.v., the peak drug concentration in heart occurred in 30 min following administration of free Adriamycin or Adriamycin entrapped in negative liposomes, compared to 5 min with Adriamycin entrapped in positive liposomes. The maximum drug concentration achieved with positive liposomes in cardiac tissue was approximately one-half that of free drug or drug entrapped in negative liposomes. In addition, the cardiac concentration x time values for Adriamycin administered in positive liposomes were considerably less than that of free drug or negative liposomes for the 24-hr period of observation. The liposomal Adriamycin was preferentially concentrated in liver, spleen, and lungs. Electron microscopic studies demonstrated that the myocytes and myofibrillar structure of cardiac muscle were markedly well preserved with Adriamycin in positive liposomes, in contrast to the two other delivery forms. The antitumor activity of the drug against murine ascitic P388 leukemia and Lewis lung carcinoma demonstrated an identical effect when administered as free drug or entrapped in positive liposomes. The specific positively charged liposome developed in these studies selectively reduces the acute cardiotoxicity of Adriamycin without loss of antitumor activity.

1 This investigation was supported in part by National Cancer Institute Contract NO 1 CM 97310 from the NIH, Bethesda, Md.

2 To whom requests for reprints should be addressed, at Division of Medical Oncology, Georgetown University Hospital, 3800 Reservoir Rd., N. W., Washington, D. C. 20007.

Received 9/ 7/79. Accepted 2/ 6/80.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. A. Abraham, C. McKenzie, D. Masin, R. Ng, T. O. Harasym, L. D. Mayer, and M. B. Bally
In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading
Clin. Cancer Res., January 15, 2004; 10(2): 728 - 738.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
J. Patel
Liposomal doxorubicin: Doxil(R)
Journal of Oncology Pharmacy Practice, December 1, 1996; 2(4): 201 - 210.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.